YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SAN FRANCISCO, October 08, 2026--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-ce…
Earnings Call Insights: Vir Biotechnology (VIR) Q2 2026 MANAGEMENT VIEW * Dr. Marianne De Backer (President, CEO & Director) said Vir is “entering a catalyst-rich period for hepatitis delta,” after completing enrollment in ECLIPSE 2 and fi…
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls' thesis on VIR. Vir Biotechnology, Inc.'s share was trading at $9.19 as…
Key Points Superstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices. The quarter-end position value rose $6.55 million, reflecting the new s…
Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened Ac…
SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology(NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing. What happened According to an SEC f…
Key Points Boxer Capital Management increased its Vir Biotechnology stake by 1,241,000 shares in the first quarter; the estimated trade size was $9.89 million. Meanwhile, the quarter-end position value rose by $12.95 million, reflecting bo…
On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Com…
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest batt…
Vicki L. Sato, Chairman of the Board of Directors of Vir Biotechnology(NASDAQ:VIR), reported the sale of 22,000 shares of common stock for a total value of approximately $221,000 according to a SEC Form 4 filing. Transaction summary Metric…
Key Points Vicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share. This trade represented 2% of Sato's direct holdings, reducing her position from 1.10 million to 1,078,391 shar…
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Platform Validation The closing of the Astellas collaboration for VIR-5500 validates the PROXTEN dual-masking platform, which is designed to widen the the…
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.2 per share a year ago. These figures are adjusted for non-recurring…
Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.'s share was trading at $11.09 as of…
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnolog…
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the best low priced biotech stocks to invest in. On April 13, Vir Biotechnology, Inc. (NASDAQ:VIR) announced that the first patient had been dosed in one of three expansion cohorts in the Phas…
Key Points 72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction. The transaction involved only direct holdings, with n…
President and CEO Marianne De Backer of Vir Biotechnology, Inc., reported the sale of 72,559 shares in an open-market transaction on April 6, 2026, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 72…
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund started the year optimistically, expecting fiscal and monetary policies to boost an economy showing…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Vir Biotechnology (NasdaqGS:VIR) announced a global collaboration with Astellas Pharma to develop and commercialize VIR-5500…
This article first appeared on GuruFocus. Revenue: EUR1.5 billion for the full year 2025. EBITDA: EUR441 million, with a margin of 30.1%. Net Income: EPS of EUR6.24. Cash Generation: EUR200 million, enabling debt reduction. Net Debt: Reduc…
The big news this week is AI may not be the economic savior that companies were hoping for. Sure, AI will help cut costs and make companies more profitable. At least, initially. What happens next is the big question. Claim 50% Off TipRanks…
Advanced Micro Devices, Inc. (AMD) shares rose 8.8% after Meta Platforms, Inc. (META) announced a multiyear deal using AMD GPUs for AI data centers. Vir Biotechnology, Inc. (VIR) shares surged 27.7% on positive updated Phase 1 results for…
* Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) announced [https://seekingalpha.com/pr/20412007-vir-biotechnology-announces-proposed-public-offering-of-common-stock] plans to offer $200M of its common stock in an underwritt…
Check out the companies making headlines in midday trading: Dillard's — Shares fell 7% after the department store posted weaker-than-expected revenue in the holiday quarter. Fourth-quarter revenue came in at $1.99 billion, while analysts p…
Market Catalysts Host Julie Hyman and Yahoo Finance Markets and Data Editor Jared Blikre tracks several of the day's top trending stock tickers, including Anthropic (ANTH.PVT) announcing new tools for its Claude AI chatbot, Keurig Dr Peppe…
Vir stock catapulted Tuesday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma. Continue Reading
Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate. Continue Reading
March S&P 500 E-Mini futures (ESH26) are down -0.04%, andMarch Nasdaq 100 E-Mini futures (NQH26) are up +0.21% this morning as sentiment remains cautious following yesterday’s selloff on Wall Street triggered by concerns over the disruptiv…
(RTTNews) - Shares of Vir Biotechnology, Inc. (VIR) surged more than 50% in overnight trading after the company announced a global strategic collaboration with Astellas Pharma for its PSMA-targeting T-cell engager, VIR-5500, and released u…
Earnings Call Insights: Vir Biotechnology, Inc. (VIR) Q4 2025 MANAGEMENT VIEW * Marianne De Backer, CEO, announced a strategic collaboration with Astellas for the global development and commercialization of VIR-5500, describing it as "our…
Image source: The Motley Fool. DATE Monday, Feb. 23, 2026 at 5:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Marianne De BackerChief Medical Officer — Dr. Mark D. EisnerChief Financial Officer — Jason O’ByrneConsulting Clinica…
Vir stock catapulted late Monday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma. Continue Reading
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, a…
[New York City and London multiple exposure image] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY -…
[Hepatitis Concept] eenevski/iStock via Getty Images * Vir Biotechnology (VIR [https://seekingalpha.com/symbol/VIR]) has granted Norgine Pharma UK an exclusive license to market its experimental chronic hepatitis d treatment, a combination…